Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Subscribe To Our Newsletter & Stay Updated
